{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-157998","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.421048+00:00","generated_at":"2026-06-14T10:16:25.231242+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lyra Therapeutics announces $50M private placement; extends cash runway into Q1 2025","bullets":["Gross proceeds of ~$50M from sale of ~17.7M shares, ~2.4M pre-funded warrants, and ~10.0M purchase warrants at $2.4925 per unit.","Pre-funded warrants exercisable immediately at $0.001/share, expire May 2028; purchase warrants exercisable from Nov 2023 at $2.673/share, expire Nov 2028.","Cash, cash equivalents and short-term investments stood at $82.7M as of Q1 2023; combined with net proceeds expected to fund operations into Q1 2025.","Cantor Fitzgerald and William Blair acted as joint lead placement agents; H.C. Wainwright as co-placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-157998","json":"https://secwatch.observer/filing/0001193125-23-157998.json","markdown":"https://secwatch.observer/filing/0001193125-23-157998.md","text":"https://secwatch.observer/filing/0001193125-23-157998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/0001193125-23-157998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/d515559d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:16:25.231242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"936990cf2ed656d53c1ac75f58ab269a72c03770","claim":"Lyra Therapeutics, Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at aggregate gross proceeds of approximately $50.0 million (effective 2023-05-25).","evidence_excerpt":"On May 25, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to sell securities to the Investors in a private placement (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/0001193125-23-157998-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers named therein"},{"label":"Value","value":"aggregate gross proceeds of approximately $50.0 million"},{"label":"Effective","value":"2023-05-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}